Epidural administration of tiletamine-zolazepam in horses.

This small double-blind crossover study in five healthy horses tested two caudal epidural doses of tiletamine–zolazepam and found short-term, moderate analgesia of the perineal region with observable sedation and ataxia, without significant cardiovascular or respiratory changes. Because spinal toxicity data for this drug combination are lacking, the authors advise caution and do not recommend routine clinical use yet.

What the researchers asked and why it matters

• Question: Does caudal epidural tiletamine–zolazepam (Telazol) provide effective analgesia in horses, and what are its cardiorespiratory and behavioral effects?
• Clinical need: Managing pain in the perineal/caudal regions (e.g., tail, anus, vulva, perineum) can be challenging; a short-acting epidural option could facilitate minor procedures while keeping horses standing.
• Rationale: Tiletamine (a dissociative NMDA antagonist) combined with zolazepam (a benzodiazepine) provides injectable anesthesia systemically; its epidural effects in equids had not been defined, and spinal safety was unknown.

Study design at a glance

• Design: Prospective, randomized, double-blind, within-subject (crossover) experimental study.
• Animals: Five adult healthy horses (10–16 years; mean weight 400 ± 98 kg).
• Preparation: Each horse was sedated once with IV xylazine 1.0 mg/kg to place a caudal epidural catheter at the first intercoccygeal space (Co1–Co2); drug testing occurred after a 48-hour rest (i.e., without concurrent xylazine effects).
• Treatments (random order, 1-week washout):
  • Treatment I: Epidural tiletamine–zolazepam 0.5 mg/kg diluted to 5 mL sterile water.
  • Treatment II: Epidural tiletamine–zolazepam 1.0 mg/kg diluted to 5 mL sterile water.
• Blinding: Investigators assessing outcomes were blinded to dose.

What was measured

• Analgesia: Response to a standardized noxious pressure stimulus (blunt-tipped forceps) on the perineal region; graded as complete, moderate, or absent.
• Sedation and behavior: Clinical sedation scoring and observation for locomotor ataxia.
• Cardiorespiratory variables: Heart rate, respiratory rate, and arterial blood pressure at baseline and every 15 minutes for 120 minutes, plus at 4 hours.
• Respiratory gas exchange: Carotid arterial blood sampling at baseline, 60 minutes, and 240 minutes.
• Timing: Baseline pre-dose; repeated assessments every 15 minutes for 2 hours; a final assessment at 4 hours.
• Statistics: ANOVA with Bonferroni post hoc testing; significance set at p < 0.05.

Key results

• Analgesia:
  • Both doses produced moderate analgesia to perineal pressure stimulation.
  • Analgesia was characterized as short-term and did not consistently reach complete blockade.
  • No clear superiority of the higher dose over the lower dose was demonstrated.
• Sedation and motor effects:
  • Sedation occurred with both doses.
  • Sedation was statistically greater than baseline at 60, 75, and 90 minutes with the 1.0 mg/kg dose.
  • Locomotor ataxia was observed with both doses, indicating impaired coordination during the effect window.
• Cardiovascular and respiratory effects:
  • No significant differences between the two doses in heart rate, respiratory rate, or arterial blood pressure.
  • Arterial blood gas analyses at 60 and 240 minutes did not show significant respiratory compromise compared with baseline.

Interpretation and clinical relevance

• Efficacy: Caudal epidural tiletamine–zolazepam increased the nociceptive threshold to pressure in the perineal region, yielding moderate, short-lived analgesia suitable only for minor, brief procedures in that dermatomal distribution.
• Dose–response: The lack of significant difference between 0.5 and 1.0 mg/kg suggests a shallow dose–response within this range or insufficient power to detect differences; the higher dose did produce more pronounced sedation at specific time points.
• Safety profile: Within the monitoring period, cardio-respiratory parameters remained stable, but the presence of sedation and ataxia limits use in situations requiring secure footing or precise motor control.
• Geographic spread: Caudal epidural placement targets sacrococcygeal segments; effects localized to perineal/tail regions are expected and consistent with the observed analgesia pattern.

Strengths and limitations

• Strengths:
  • Prospective, randomized, double-blind crossover design controls for inter-horse variability.
  • Standardized nociceptive testing and objective physiologic monitoring.
• Limitations:
  • Very small sample size (n = 5) limits statistical power and generalizability.
  • Analgesia assessed only with a pressure stimulus on the perineum; effects on other modalities (thermal, mechanical pinprick) or regions were not evaluated.
  • Monitoring extended to 4 hours; longer-duration effects or delayed adverse events were not assessed.
  • No histopathology or neurotoxicity assessment; spinal safety of tiletamine–zolazepam remains unknown.

Safety and risk considerations

• Neurotoxicity: There are no studies examining spinal (epidural/intrathecal) toxicity of tiletamine–zolazepam; this is the central barrier to recommending clinical use.
• Motor impairment: Observed locomotor ataxia raises handling and patient-safety concerns for standing procedures.
• Systemic effects: Sedation may reflect epidural spread or systemic absorption; while cardiorespiratory variables were stable here, vigilant monitoring is warranted.
• Technique sensitivity: Accurate caudal epidural placement and strict asepsis are essential to minimize complications; inadvertent intrathecal injection would increase risk.

Practical takeaways

• What it can do: Provide short-term, moderate analgesia of the perineal region in standing horses.
• What it cannot reliably do: Produce consistent complete sensory blockade or long-duration analgesia; avoid motor effects.
• Dose guidance from this study: 0.5 and 1.0 mg/kg performed similarly for analgesia, with more noticeable sedation at 1.0 mg/kg.
• Current stance: Given unknown spinal toxicity, routine clinical adoption is not recommended pending further safety research.

Future directions

• Define spinal safety: Histopathologic and neurologic evaluations after epidural and intrathecal exposure to tiletamine–zolazepam in equids.
• Optimize dosing: Larger, powered trials to characterize dose–response, onset, peak effect, and duration, including adjuncts that might enhance analgesia without increasing ataxia.
• Broaden outcomes: Compare against established epidural agents (e.g., alpha-2 agonists, opioids, local anesthetics) for efficacy, duration, and side-effect profiles.
• Functional impact: Quantify gait and postural stability to better define handling risks during standing procedures.